Mathias Gehrmann

4.1k citations

41 papers · 2.2k indexed · 1 hit paper · h-index 23

Impact in

Cancer Research top 2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis

Papers in

Cancer Research 16
- Breast Cancer Treatment Studies 12
- Cancer Genomics and Diagnostics 4
Oncology 25
- Cancer Cells and Metastasis 13
- HER2/EGFR in Cancer Research 13
- Cancer Immunotherapy and Biomarkers 6

Co-authors: Marcus Schmidt Jan G. Hengstler Hans‐Anton Lehr Christian von Törne Eric Steiner Henryk Pilch H. Kölbl Daniel Böhm
Journals: Journal of Clinical Oncology (6 papers)Clinical Cancer Research (4 papers)British Journal of Cancer (3 papers)Breast Cancer Research and Treatment (3 papers)BMC Cancer (2 papers)
Partner nations: Germany Switzerland Austria

In The Last Decade

Mathias Gehrmann

39 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer 2008 · 588 citations

Peers

Countries citing papers authored by Mathias Gehrmann

Since Specialization

Citations

This map shows the geographic impact of Mathias Gehrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathias Gehrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathias Gehrmann more than expected).

Fields of papers citing papers by Mathias Gehrmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mathias Gehrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathias Gehrmann. The network helps show where Mathias Gehrmann may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mathias Gehrmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mathias Gehrmann Line = papers co-authored together Mathias Gehrmann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer European Journal of Cancer ·Katrin Almstedt, Anne-Sophie Heimes, Franziska Kappenberg, Marco Johannes Battista, Hans‐Anton Lehr, Slavomir Krajnak, Antje Lebrecht, Mathias Gehrmann, Ni Putu Ayu Nikita Sari Wulan, Walburgis Brenner, W. Weikel, Jörg Rahnenführer, Jan G. Hengstler, Annette Hasenburg, Marcus Schmidt	2022	60
2	Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer Cancers ·Marcus Schmidt, Karolina Edlund, Jan G. Hengstler, Anne-Sophie Heimes, Katrin Almstedt, Antje Lebrecht, Slavomir Krajnak, Marco Johannes Battista, Walburgis Brenner, Annette Hasenburg, Jörg Rahnenführer, Mathias Gehrmann, Pirkko‐Liisa Kellokumpu‐Lehtinen, Ralph M. Wirtz, Heikki Joensuu	2021	1
3	The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients British Journal of Cancer ·(unknown), Peter Dubsky, Jan C. Brase, R. Jakesz, Margaretha Rudas, Christian F. Singer, Richard Greil, Otto Dietze, 陈扬林, DAVID ALEJANDRO PORRAS CORREA, Roland Sedivy, M. Bachner, Doris Mayr, Marcus Schmidt, Mathias Gehrmann, Christoph Petry, Karsten E. Weber, Anastasios G. Kriebardis, Ralf Kronenwett, Michael Gnant, Martin Filipits	2013	235
4	Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients BMC Cancer ·Wulf Siggelkow, Daniel Boehm, Susanne Gebhard, Marco Johannes Battista, Uwimana Sebinwa, Antje Lebrecht, Christine Solbach, Birte Hellwig, Jörg Rahnenführer, Heinz Koelbl, Mathias Gehrmann, Rosemarie Marchan, Cristina Cadenas, Jan G. Hengstler, Marcus Schmidt	2012	45
5	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer Annals of Oncology ·Peter Dubsky, Martin Filipits, R. Jakesz, Margaretha Rudas, Christian F. Singer, Richard Greil, Otto Dietze, 陈扬林, DAVID ALEJANDRO PORRAS CORREA, Roland Sedivy, M. Bachner, Doris Mayr, Marcus Schmidt, Mathias Gehrmann, Christoph Petry, Karsten E. Weber, Ralf Kronenwett, Jan C. Brase, Michael Gnant	2012	129
6	Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer British Journal of Cancer ·Silvia Darb‐Esfahani, Ralf Kronenwett, Gϋnter von Minckwitz, Carsten Denkert, Mathias Gehrmann, Achim Rody, Jan Budczies, Jan C. Brase, THALITA CUNHA MOTTA, Hans Bojar, Beyhan Ataseven, Thomas Karn, (unknown), Dilmurod Nasimov, F Khandan, Manfred Dietel, Sibylle Loibl	2012	16
7	Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors OncoImmunology ·Marcus Schmidt, Patrick Micke, Mathias Gehrmann, Jan G. Hengstler	2012	26
8	Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer PLoS ONE ·Zonglin Chen, Aslihan Gerhold‐Ay, Susanne Gebhard, Daniel Boehm, Christine Solbach, Antje Lebrecht, Marco Johannes Battista, Uwimana Sebinwa, Christina Cotarelo, Cristina Cadenas, Rosemarie Marchan, Joanna D. Stewart, Mathias Gehrmann, Heinz Koelbl, Jan G. Hengstler, Marcus Schmidt	2012	30
9	ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction Clinical Cancer Research ·Jan C. Brase, Marcus Schmidt, Thomas Fischbach, Holger Sültmann, Hans Bojar, Heinz Koelbl, Birte Hellwig, Jörg Rahnenführer, Jan G. Hengstler, Mathias Gehrmann	2010	108
10	New prognostic and predictive factors in breast cancer. PubMed ·Marcus Schmidt, Mathias Gehrmann, Jan G. Hengstler, Heinz Koelbl	2010	6
11	Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer Breast Cancer Research ·Cristina Cadenas, Weidong Dong, Marcus Schmidt, Mathias Gehrmann, Matthias Hermes, H. Caddy, Wiebke Schormann, Lindsey Maccoux, Markus Schug, Anika Schumann, Christian Wilhelm, Aitana Terrero-Anguiano, Katja Ickstadt, Jörg Rahnenführer, Jan Baumbach, Albert Sickmann, Jan G. Hengstler	2010	143
12	Integration of pathway knowledge into a reweighted recursive feature elimination approach for risk stratification of cancer patients Bioinformatics ·Marc Johannes, Jan C. Brase, Holger Fröhlich, Stephan Gade, Mathias Gehrmann, Maria Fälth, Holger Sültmann, Tim Beißbarth	2010	75
13	Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer Breast Cancer Research and Treatment ·Marcus Schmidt, Ilka Petry, Daniel Böhm, Antje Lebrecht, Christian von Törne, Susanne Gebhard, Aslihan Gerhold‐Ay, Brenda J. Latka, Marco Johannes Battista, Wiebke Schormann, Aitana Terrero-Anguiano, Silvia Selinski, Katja Ickstadt, Jörg Rahnenführer, Martin Sebastian, Martin Schüler, Heinz Koelbl, Mathias Gehrmann, Jan G. Hengstler	2010	29
14	Coordinates in the Universe of Node-Negative Breast Cancer Revisited Cancer Research ·Marcus Schmidt, Jan G. Hengstler, Christian von Törne, Heinz Koelbl, Mathias Gehrmann	2009	28
15	The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer Cancer Research ·Marcus Schmidt, Daniel Böhm, Christian von Törne, Eric Steiner, Alexander Puhl, Henryk Pilch, Hans‐Anton Lehr, Jan G. Hengstler, H. Kölbl, Mathias Gehrmann Hit paper breakdown →	2008	588
16	Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer Clinical Cancer Research ·Marcus Schmidt, Dirk Hasenclever, William Monkarsh, Daniel Boehm, Brenda J. Latka, Eric Steiner, Antje Lebrecht, Wulf Siggelkow, W. Weikel, Priscila de Souza Ramos, Susanne Gebhard, Henryk Pilch, Mathias Gehrmann, Hans‐Anton Lehr, Heinz Koelbl, Jan G. Hengstler, Martin Schüler	2008	69
17	Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer Breast Cancer Research and Treatment ·Achim Rody, Thomas Karn, Eugen Ruckhäberle, Volkmar Müller, Mathias Gehrmann, Christine Solbach, A. Ahr, R. Gätje, Uwe Holtrich, M. Kaufmann	2008	52
18	Poor Outcome in Estrogen Receptor–Positive Breast Cancers Predicted by Loss of Plexin B1 Clinical Cancer Research ·Achim Rody, Uwe Holtrich, R. Gaetje, Mathias Gehrmann, Knut Engels, Gϋnter von Minckwitz, Sibylle Loibl, Chao Jiang, Eugen Ruckhäberle, Dirk Metzler, A. Ahr, Christine Solbach, Thomas Karn, Manfred Kaufmann	2007	54
19	Role of the progesterone receptor for paclitaxel resistance in primary breast cancer British Journal of Cancer ·Marcus Schmidt, E. Bremer, Dirk Hasenclever, Anja Victor, Mathias Gehrmann, Eric Steiner, Ilka B. Schiffer, G. Gebhardt, Umit Ciftci, Marta Wojcieszak, Matthias Hermes, Alexander Mustea, B. Tanner, Heinz Koelbl, Henryk Pilch, Jan G. Hengstler	2007	21
20	Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis Osteoarthritis and Cartilage ·Xavier Chevalier, T Conrozier, Mathias Gehrmann, Pascal Claudepierre, Pierre Mathieu, S. Unger, E. Vignon	2001	39

About Mathias Gehrmann

Mathias Gehrmann is a scholar working on Cancer Research, Oncology, Cell Biology, Molecular Biology and Biophysics, having authored 41 papers that have together received 2.2k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (13 papers), HER2/EGFR in Cancer Research (13 papers), Breast Cancer Treatment Studies (12 papers), Cancer Immunotherapy and Biomarkers (6 papers), Cancer Genomics and Diagnostics (4 papers), Gene expression and cancer classification (4 papers), Bioinformatics and Genomic Networks (3 papers) and Estrogen and related hormone effects (3 papers). The work is most often cited by research in Cancer Research (884 citations), Oncology (1.1k citations), Immunology (326 citations), Molecular Biology (1.0k citations) and Pulmonary and Respiratory Medicine (335 citations). Mathias Gehrmann has collaborated with scholars based in Germany, Switzerland and Austria. Frequent co-authors include Marcus Schmidt, Jan G. Hengstler, Hans‐Anton Lehr, Christian von Törne, Eric Steiner, Henryk Pilch, H. Kölbl, Daniel Böhm, Alexander Puhl and Jan C. Brase. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, British Journal of Cancer, Breast Cancer Research and Treatment and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact